SURUNKALI GLOMERULONEFRITDA TUBULOINTERSTITSIAL FIBROZNI ERTA TASHXISLASHDA NOINVAZIV BIOMARKERLARNING (KIM-1, NGAL, TIMP-1) O‘RNI
Ключевые слова:
surunkali glomerulonefrit, tubulointerstitsial fibroz, noinvaziv biomarkerlar, KIM-1, NGAL, TIMP-1, nefroproteksiyaАннотация
Surunkali glomerulonefrit (SGN) oqibatida terminal buyrak yetishmovchiligi rivojlanishining asosiy determinanti tubulointerstitsial fibroz (TIF) hisoblanadi. Buyrak biopsiyasi TIFni aniqlashda "oltin standart" bo‘lsa-da, uning invazivligi va takroriy qo‘llash imkoniyati cheklanganligi sababli, amaliyotda buyrak gistoarxitektonikasidagi sklerotik o‘zgarishlarni aks ettiruvchi noinvaziv va sezgir biomarkerlarni izlash dolzarb masala bo‘lib qolmoqda.
Библиографические ссылки
Gilbert, R. E. (2023). Tubulointerstitial Fibrosis in Chronic Kidney Disease: Signaling Pathways and Cell-Type Specification. International Journal of Molecular Sciences, 24(11), 9432.
Humphreys, B. D. (2024). Mechanisms of Renal Fibrosis. Annual Review of Physiology, 86, 423-445.
Ichimura, T., Brooks, C. R., & Bonventre, J. V. (2020). Kim-1/Tim-1: a kidney injury molecule with diverse functions in immunity and tissue repair. American Journal of Physiology-Renal Physiology, 318(5), F1085-F1098.
Sato, Y., & Yanagita, M. (2021). Histopathology of tubular injury and interstitial fibrosis in chronic glomerulonephritis. Clinical and Experimental Nephrology, 25(8), 795-804.
Parikh, C. R., & Bonventre, J. V. (2022). Biomarkers of kidney injury and repair: from bedside to bench and back. Kidney International, 101(4), 682-695.
Devarajan, P. (2021). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker of kidney disease: an update. Pediatric Nephrology, 36(11), 3455-3467.
Nangaku, M. (2022). Chronic hypoxia as a common mechanism of chronic kidney disease progression. Journal of the American Society of Nephrology, 33(3), 485-492.
Viau, A., El Karoui, K., & Terzi, F. (2023). Lipocalin 2 and NGAL in chronic kidney disease: a double-edged sword. Frontiers in Physiology, 14, 1120491.
Coca, S. G., & Parikh, C. R. (2022). Urinary biomarkers for the evaluation of chronic kidney disease progression. Current Opinion in Nephrology and Hypertension, 31(6), 523-531.
Zakiyanov, O., Kalousová, M., & Tesař, V. (2021). Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Chronic Kidney Disease. Biomolecules, 11(12), 1853.
Meng, X. M., Nikolic-Paterson, D. J., & Lan, H. Y. (2022). TGF-beta: the principal driver of kidney fibrosis. Nature Reviews Nephrology, 18(6), 345-364.
Eddy, A. A. (2024). Cellular and molecular mechanisms of renal tubulointerstitsial fibrosis. Kidney International Supplements, 14(1), 12-25.
Zeisberg, M., & Kalluri, R. (2023). Cellular mechanisms of tissue fibrosis. 1. Renal fibrosis. American Journal of Physiology-Cell Physiology, 324(2), C213-C224.
Nkuipou-Kenfack, E., & Mischak, H. (2024). Multimarker panels vs. single biomarkers in chronic kidney disease prognosis. Proteomics – Clinical Applications, 18(2), e2300045.
Perco, P., & Mayer, G. (2025). Non-invasive evaluation of renal fibrosis: Current status and future perspectives. Nephrology Dialysis Transplantation, 40(1), 102-114.
Загрузки
Опубликован
Выпуск
Раздел
Как цитировать
